BioAlliance wins FDA approval for anti-fungal therapy

BioAlliance Pharma SA said that it has won approval from the US Food and Drug Administration to market its anti-fungal therapy, Loramyc, to treat patients whose immune systems have been compromised following chemotherapy or radiotherapy.

Location